about
Gene expression analysis in RA: towards personalized medicineRelationship between the type I interferon signature and the response to rituximab in rheumatoid arthritis patientsThe gene expression profile in the synovium as a predictor of the clinical response to infliximab treatment in rheumatoid arthritisFeatures of the synovium of individuals at risk of developing rheumatoid arthritis: implications for understanding preclinical rheumatoid arthritisHeterogeneous expression pattern of interleukin 17A (IL-17A), IL-17F and their receptors in synovium of rheumatoid arthritis, psoriatic arthritis and osteoarthritis: possible explanation for nonresponse to anti-IL-17 therapy?Rheumatoid arthritis subtypes identified by genomic profiling of peripheral blood cells: assignment of a type I interferon signature in a subpopulation of patients.Interleukin 1 receptor antagonist mediates the beneficial effects of systemic interferon beta in mice: implications for rheumatoid arthritisTranscription profiling of rheumatic diseasesLymph node biopsy analysis reveals an altered immunoregulatory balance already during the at-risk phase of autoantibody positive rheumatoid arthritis.Inflammatory cytokines epigenetically regulate rheumatoid arthritis fibroblast-like synoviocyte activation by suppressing HDAC5 expressionType I IFN and TNFα cross-regulation in immune-mediated inflammatory disease: basic concepts and clinical relevance.Fibroblast-like synoviocytes derived from patients with rheumatoid arthritis show the imprint of synovial tissue heterogeneity: evidence of a link between an increased myofibroblast-like phenotype and high-inflammation synovitis.Molecular subtypes of systemic sclerosis in association with anti-centromere antibodies and digital ulcers.Human lymph-node CD8(+) T cells display an altered phenotype during systemic autoimmunity.Type I interferons have no major influence on humoral autoimmunity in rheumatoid arthritis.Pharmacogenomics of infliximab treatment using peripheral blood cells of patients with rheumatoid arthritis.Brief Report: Altered Innate Lymphoid Cell Subsets in Human Lymph Node Biopsy Specimens Obtained During the At-Risk and Earliest Phases of Rheumatoid Arthritis.JNK-dependent downregulation of FoxO1 is required to promote the survival of fibroblast-like synoviocytes in rheumatoid arthritis.Tertiary Lymphoid Structures in Rheumatoid Arthritis: NF-κB-Inducing Kinase-Positive Endothelial Cells as Central Players.Evaluating antirheumatic treatments using synovial biopsy: a recommendation for standardisation to be used in clinical trialsHuman keratinocytes express functional Toll-like receptor 3, 4, 5, and 9A subtype of multiple sclerosis defined by an activated immune defense programGene expression profiling in autoantibody-positive patients with arthralgia predicts development of arthritisSynovial tissue heterogeneity in rheumatoid arthritis in relation to disease activity and biomarkers in peripheral bloodMyeloid Dendritic Cells Are Enriched in Lymph Node Tissue of Early Rheumatoid Arthritis Patients but not in At Risk Individuals
P50
Q26825706-BB1D567C-7D31-4594-A517-EC40C886FA34Q28290930-003D2AC7-7951-4BD8-8373-A59D478FEB06Q28751012-957EC27D-962E-4F67-9E0D-690635CBD5A8Q33667747-49F5C4E1-51D0-4828-8273-E2DD885CF876Q34937925-1386B12B-3AD8-43F6-A851-C1B0721DBAC6Q35953527-F8E4C1B6-73A7-4DCA-B01F-7BE1980053B5Q37058559-65559CB1-701B-4309-B8F1-9357BB9318A5Q37207014-7A977971-3B59-443F-A86B-FBD14F603891Q37505439-F8284682-9828-441F-8777-7B3EA5EA58A5Q37679886-B22D1B27-FDC8-4BDB-8B6F-B52DA1C0525CQ37808291-9EF01FED-1ECF-4484-BD3E-46F13D7B165FQ38330976-E4F88DE0-8C62-4F5E-9FF6-5EBB2311CAD9Q38511253-5951D72D-C2EB-4E2F-9B66-C998AF0D520AQ40946470-92517C0F-D7B8-4E83-87E3-1B9193B8747BQ44893396-07A5CDFA-AED7-4F11-BD2B-F98DD949F874Q46325862-5F634732-C971-4483-BFD7-08CEF6B151EAQ51634683-67A94BB4-1CD3-49FF-9F75-2C37ED45D811Q53052194-0F187D92-A47C-4ED6-9E08-B992B277282BQ53511015-3704B384-364B-40B1-9ADB-80E0EC7ED841Q57231953-43B244B9-1488-4886-8A71-464C30828C5FQ79306611-9921935F-EA94-43EC-A8EC-448C517BD9C9Q79894728-83003164-DA74-48FA-888F-A18C0BA9C1F3Q82777541-DD931E05-A5FC-4E9C-92F9-E72B0E51161EQ83006833-06C1A347-137F-4168-B0E5-21EA63856C41Q92081744-BB7DA6B4-BB84-4BD9-ADCD-73AAF8ECD0AC
P50
description
researcher ORCID ID = 0000-0003-3346-8921
@en
wetenschapper
@nl
name
Lisa G van Baarsen
@ast
Lisa G van Baarsen
@en
Lisa G van Baarsen
@es
Lisa G van Baarsen
@nl
type
label
Lisa G van Baarsen
@ast
Lisa G van Baarsen
@en
Lisa G van Baarsen
@es
Lisa G van Baarsen
@nl
prefLabel
Lisa G van Baarsen
@ast
Lisa G van Baarsen
@en
Lisa G van Baarsen
@es
Lisa G van Baarsen
@nl
P106
P1153
6507626221
P21
P31
P496
0000-0003-3346-8921